{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:16:01Z","timestamp":1777947361820,"version":"3.51.4"},"reference-count":51,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The efficacy of aprotinin combinations with selected antiviral-drugs treatment of influenza virus and coronavirus (SARS-CoV-2) infection was studied in mice models of influenza pneumonia and COVID-19. The high efficacy of the combinations in reducing virus titer in lungs and body weight loss and in increasing the survival rate were demonstrated. This preclinical study can be considered a confirmatory step before introducing the combinations into clinical assessment.<\/jats:p>","DOI":"10.3390\/molecules27154975","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T22:33:11Z","timestamp":1659997991000},"page":"4975","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2"],"prefix":"10.3390","volume":"27","author":[{"given":"Andrey A.","family":"Ivashchenko","sequence":"first","affiliation":[{"name":"ChemDiv Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan A.","family":"Zagribelnyy","sequence":"additional","affiliation":[{"name":"ChemDiv Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan A.","family":"Ivanenkov","sequence":"additional","affiliation":[{"name":"ChemDiv Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya A.","family":"Ivashchenko","sequence":"additional","affiliation":[{"name":"ChemDiv Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben N.","family":"Karapetian","sequence":"additional","affiliation":[{"name":"ChemDiv Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry V.","family":"Kravchenko","sequence":"additional","affiliation":[{"name":"ChemDiv Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolay P.","family":"Savchuk","sequence":"additional","affiliation":[{"name":"Viriom Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena V.","family":"Yakubova","sequence":"additional","affiliation":[{"name":"Viriom Inc., San Diego, CA 92130, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre V.","family":"Ivachtchenko","sequence":"additional","affiliation":[{"name":"ChemDiv Inc., San Diego, CA 92130, USA"},{"name":"ASAVI LLC, 1835 E. Hallandale Beach Blvd, #442, Hallandale Beach, FL 33009, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"ref_1","first-page":"157","article-title":"WHO Declares COVID-19 a Pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed."},{"key":"ref_2","unstructured":"(2022, June 07). COVID-19 Coronavirus Pandemic. Worldometer. Available online: https:\/\/www.worldometers.info\/coronavirus."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.2147\/IJGM.S332458","article-title":"Effectiveness of Remdesivir, Lopinavir\/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review","volume":"14","author":"Qomara","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/jmv.27730","article-title":"Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2\u2014A narrative review","volume":"94","author":"Masyeni","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1002\/jmv.26990","article-title":"A brief review of influenza virus infection","volume":"93","author":"Javanian","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_6","unstructured":"CDC, and NCIRD (2021, September 29). Disease Burden of Flu, Available online: https:\/\/www.cdc.gov\/flu\/about\/burden\/index.html."},{"key":"ref_7","unstructured":"CDC (2021, September 29). Archived: Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths in the United States\u20142019\u20132020 Influenza Season, Available online: https:\/\/www.cdc.gov\/flu\/about\/burden\/2019\u20132020\/archive-09292021.html."},{"key":"ref_8","unstructured":"CDC (2022, June 13). Influenza Antiviral Medications: Summary for Clinicians, Available online: https:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/summary-clinicians.htm."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bai, Y., Jones, J.C., Wong, S.-S., and Zanin, M. (2021). Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance. Viruses, 13.","DOI":"10.3390\/v13040624"},{"key":"ref_10","first-page":"1198","article-title":"Treatment with neuraminidase inhibitors for critically ill patients with nfluenza A (H1N1) pdmClin","volume":"55","author":"Louie","year":"2012","journal-title":"Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1093\/jac\/dku074","article-title":"Novel oral anti-influenza drug candidate AV5080","volume":"69","author":"Ivachtchenko","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bojkova, D., Bechtel, M., McLaughlin, K.M., McGreig, J.E., Klann, K., Bellinghausen, C., Rohde, G., Jonigk, D., Braubach, P., and Ciesek, S. (2020). Aprotinin Inhibits SARS-CoV-2 Replication. Cells, 9.","DOI":"10.3390\/cells9112377"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0022-5223(99)70226-6","article-title":"Aprotinin in fibrin tissue adhesives induces. specific antibody response and increases antibody response of high-dose intravenous application","volume":"118","author":"Scheule","year":"1999","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5223(19)34573-8","article-title":"Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol)","volume":"97","author":"Bidstrup","year":"1989","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/0167-5273(96)02572-7","article-title":"Preventing the inflammatory response to open-heart surgery: The role of aprotinin and other protease inhibitors","volume":"53","author":"Royston","year":"1996","journal-title":"Int. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1213\/00000539-199704000-00032","article-title":"Aprotinin reduces blood loss in patients undergoing elective liver resection Affiliations expand","volume":"84","author":"Lentschener","year":"1997","journal-title":"Anesth. Analg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF01314887","article-title":"A modified plaque assay method for accurate analysis of infectivity of influenza viruses with uncleaved hemagglutinin","volume":"71","author":"Zhirnov","year":"1982","journal-title":"Arch. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1099\/0022-1317-65-1-191","article-title":"Suppression of Influenza Virus Replication in Infected Mice by Protease lnhibitors","volume":"65","author":"Zhirnov","year":"1984","journal-title":"J. Gen. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2011.07.014","article-title":"Aprotinin and similar protease inhibitors as drugs against influenza","volume":"92","author":"Zhirnov","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2017.07.016","article-title":"TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections","volume":"142","author":"Shen","year":"2017","journal-title":"Biochimie"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12985-020-01323-z","article-title":"H2 influenza A virus is not pathogenic in Tmprss2 knock-out mice","volume":"17","author":"Lambertz","year":"2020","journal-title":"Virol. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e00754-20","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-Antimicrob","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41422-022-00619-9","article-title":"Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates","volume":"32","author":"Bojkova","year":"2022","journal-title":"Cell Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00649-19","DOI":"10.1128\/JVI.00649-19","article-title":"TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes","volume":"93","author":"Limburg","year":"2019","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wettstein, L., Kirchhoff, F., and M\u00fcnch, J. (2022). The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031351"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e202000786","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"725528","DOI":"10.3389\/fmolb.2021.725528","article-title":"Host Serine Proteases: A Potential Targeted Therapy for COVID-19 and Influenza","volume":"8","author":"Rahbar","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01309780","article-title":"Replication of influenza B virus in chicken embryos is suppressed by exogenous aprotinin","volume":"135","author":"Zhirnov","year":"1994","journal-title":"Arch. Virol."},{"key":"ref_31","first-page":"59","article-title":"Pathogenetic treatment of influenza patients with aerosolized form of aprotinin, a protease inhibitor. BIOpreparations","volume":"4","author":"Zhirnov","year":"2015","journal-title":"Prev. Diagn. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/rmv.657","article-title":"Novel insights into proteolytic cleavage of influenza virus hemagglutinin","volume":"20","author":"Bertram","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9896","DOI":"10.1128\/JVI.01118-06","article-title":"Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium","volume":"80","author":"Beyerle","year":"2006","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bertram, S., Heurich, A., Lavender, H., Gierer, S., Danisch, S., Perin, P., Lucas, J.M., Nelson, P.S., P\u00f6hlmann, S., and Soilleux, E.J. (2012). Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035876"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1038\/s41598-021-88886-1","article-title":"Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo","volume":"11","author":"Song","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3851\/IMP1715","article-title":"Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus","volume":"21","author":"Zhirnov","year":"2011","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.1128\/JVI.76.17.8682-8689.2002","article-title":"Cleavage of influenza A virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases","volume":"76","author":"Zhirnov","year":"2002","journal-title":"J. Virol."},{"key":"ref_38","unstructured":"Zhirnov, O.P., and Khanykov, A.V. (2010). Aprotinin-Based Aerosol Preparation for the Treatment of Viral Respiratory Infections. (WO\/2012\/008869)."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-Antimicrob","volume":"46","author":"Furuta","year":"2002","journal-title":"Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e00766-18","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"eaax5866","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.trsl.2019.12.002","article-title":"Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model","volume":"218","author":"Toots","year":"2020","journal-title":"Transl. Res."},{"key":"ref_44","unstructured":"Stephens, B. (2020, April 17). The Story of Remdesivir. The New York Times. Available online: https:\/\/www.nytimes.com\/2020\/04\/17\/opinion\/remdesivir-coronavirus.html."},{"key":"ref_45","unstructured":"(2020, October 22). FDA Approves First Treatment for COVID-FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19."},{"key":"ref_46","unstructured":"NIH (2021, October 27). Influenza and COVID\u2014COVID-19 Treatment Guidelines, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/special-populations\/influenza\/#:~:text=Remdesivir%20does%20not%20have%20activity,who%20are%20receiving%20oseltamivir%20treatment."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Alsafi, R., Alghamdi, S., and Asif, M. (2022). Antiviral Drugs and Their Roles in the Treatment of Coronavirus. Antiviral Drugs, Intech Open.","DOI":"10.5772\/intechopen.101717"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus\u2013Infected Pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Ivashchenko, A.A., Azarova, V.N., Egorova, A.N., Karapetian, R.N., Kravchenko, D.V., Krivonos, N.V., Loginov, V.G., Poyarkov, S.V., Merkulova, E.A., and Rosinkova, O.S. (2021). Effect of Aprotinin and Avifavir\u00ae Combination Therapy for Moderate COVID-19 Patients. Viruses, 13.","DOI":"10.3390\/v13071253"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e13776","DOI":"10.1111\/eci.13776","article-title":"Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan- protease inhibitor for moderate COVID-19","volume":"52","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(00)00123-6","article-title":"The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A\/Hong Kong\/156\/97 (H5N1) and A\/Hong Kong\/1074\/99 (H9N2) influenza virus","volume":"48","author":"Leneva","year":"2000","journal-title":"Antivir. Res."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/15\/4975\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:04:28Z","timestamp":1760141068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/15\/4975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":51,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["molecules27154975"],"URL":"https:\/\/doi.org\/10.3390\/molecules27154975","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]}}}